Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Curr Oncol
; 26(2): 108-113, 2019 04.
Article
en En
| MEDLINE
| ID: mdl-31043812
ABSTRACT
Introduction:
Diffuse large B-cell lymphoma (dlbcl) accounts for 30%-40% of all non-Hodgkin lymphomas. Approximately 60% of patients are cured with standard treatment. Targeted treatments are being investigated and might improve disease outcomes; however, their effect on cancer drug budgets will be significant. For the present study, we conducted an analysis of real-world costs for dlbcl patients treated in British Columbia, useful for health care system planning.Methods:
Patient records from a retrospective cohort of patients diagnosed with dlbcl in British Columbia during 2004-2013 were anonymously linked across multiple administrative data sources systemic therapy, radiotherapy, hospitalizations, oncologist services, outpatient medications, and fee-for-service physician services. Using generalized linear modelling regression, time-dependent costs (in 2015 Canadian dollars) were estimated in 6-month intervals over a 5-year period. The inverse probability weighting method was applied to account for censored observations. Nonparametric bootstrapping was used to estimate standard errors for the mean cost at each time interval.Results:
The cohort consisted of 678 patients (5-year overall survival 67%). Mean age at diagnosis was 64 ± 14 years; median follow-up was 3.2 years. Mean total cost of care was highest in the first 6 months after diagnosis ($29,120; 95% confidence interval $28,986 to $29,170) and after disease progression ($18,480; 95% confidence interval $15,187 to $24,772). Systemic therapy and hospitalization costs were the largest cost drivers. At each time interval, costs were observed to be positively skewed.Conclusions:
Our results depict real-world costs for the treatment of dlbcl patients with standard chop-r therapy. Cost-model parameters are also provided for economic modelling of dlbcl interventions.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Linfoma de Células B Grandes Difuso
/
Costos de la Atención en Salud
Tipo de estudio:
Health_economic_evaluation
Límite:
Aged80
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Curr Oncol
Año:
2019
Tipo del documento:
Article
Pais de publicación:
CH
/
SUIZA
/
SUÍÇA
/
SWITZERLAND